Tag: Cancer: Leukemia

Risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia elevated, but risks lower in recent years

About one-third of cases were reclassified following central review; receipt of inappropriate meds reported in 7 percent of misdiagnosed cases

Prolonged maintenance therapy for IKZF₁del improved five-year cumulative risk for relapse and event-free survival

Higher spleen volume tied to inferior overall survival and increased incidence of nonrelapse mortality for patients with AML undergoing hematopoietic stem cell transplant

Adolescent, young adult patients with overweight/obese BMI also have higher rates of grade III/IV hepatotoxicity, hyperglycemia

Findings among patients with acute myeloid leukemia and second complete remission

Overall response rates >95 percent, regardless of high-risk features; 36-month PFS 88 and 92 percent for those with, without high-risk features

Combination better than chemoimmunotherapy for percentage with undetectable minimal residual disease, PFS in chronic lymphocytic leukemia

No toxic effects seen meeting definition of primary end point; profile of toxic effects consistent with that reported in older patients

Increased risk of intracranial tumors, leukemia, and lymphoma by age 25 seen with exposure to four or more CT scans during childhood